alexa Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine | Open Access Journals
ISSN 2155-6113
Journal of AIDS & Clinical Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine

Rajnish Kumar1, Maria Luisa Visciano1, Hualin Li1 and Catarina Hioe1,2*

1New York University School of Medicine, Department of Pathology, New York, NY 10016, USA

2Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York, NY 10010, USA

*Corresponding Author:
Dr. Catarina E. Hioe
VA Medical Center, 423 East 23rd Street
Room 18-124N, New York, NY 10010, USA
Tel: 212-263-6769
Fax: 212-951-6321
E-mail: [email protected]

Received Date: February 14, 2012; Accepted Date: March 05, 2012; Published Date: March 09, 2012

Citation: Kumar R, Visciano ML, Li H, Hioe C (2012) Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. J AIDS Clinic Res S8:002. doi:10.4172/2155-6113.S8-002

Copyright: © 2012 Kumar R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research

Introduction

Efforts to develop an effective HIV vaccine have yielded disappointing results. The Vaxgen recombinant gp120 protein vaccines tested in two Phase 3 trials were unable to induce protective antibody (Ab) response [1,2], while the T-cell inducing vaccine in the Phase 2b STEP and Phambili trials delivered no apparent protection [3]. The Phase 3 RV144 trial, which evaluated a prime/boost regimen of recombinant ALVAC-HIV and two recombinant gp120 proteins, produced more promising results and suggested protective effects of anti-gp120 immunity, although the protection efficacy was low and appeared transient [4]. Thus, novel strategies are needed to create more efficacious HIV vaccines that elicit both cellular and humoral immunity, and innovative immunogens that focus Ab responses toward virus-neutralizing epitopes will be critical components for effective Abbased vaccines against HIV. This article will review our research efforts in developing a unique immune-complex vaccine platform to induce neutralizing Ab response against HIV.

HIV Envelope (Env): The Elusive Target for Broadly Neutralizing Abs

HIV Env gp120 and gp41 are the only viral antigens expressed on the surfaces of virions and infected cells [5,6]. The gp120 subunit binds to CD4 and the chemokine receptors CCR5 or CXCR4. The CD4-binding site (CD4bs) and the chemokine receptor binding site are conformational surfaces formed with discontinuous peptide segments from different gp120 regions. From the linear sequence of gp120, five variable regions, V1 to V5, and five relatively conserved regions, C1 to C5, can be traced (Figure 1). The gp41 subunit contains the fusion peptide, the trimerization domain, the transmembrane anchor, and the cytoplasmic tail. Although HIV Env is the desired target for neutralizing Abs, it displays astonishing agility in evading Ab neutralization. It is notorious for its genetic and antigenic variability, and its critical conserved epitopes are poorly immunogenic or inaccessible to Abs due to glycan and conformational masking [7-17]. During HIV infection, neutralizing Ab responses to HIV Env are generated, but they arise slowly over several months after the acute viremia peaks [18,19]. These initial neutralizing Abs are directed primarily to epitopes that readily mutate, resulting in rapid and successive emergence of escape variants. Broadly neutralizing Abs arises much later, after years of infection [20]. The reasons for the late emergence of broadly neutralizing Abs remain unclear, but several mechanisms have been postulated, including HIVinduced destruction of the lymphoid microenvironment for B cells during early stages of infection [21], requirement for repetitive continual antigen stimulations to drive B cell maturation and hypermutations that generate high-affinity IgG with long CDR3 regions characteristic of many broadly neutralizing monoclonal Abs [22-24], and modulatory effects of the early generated anti-Env Abs in shaping the repertoire of the later Ab responses [25].

aids-clinical-research-immune-vaccine-strategy

Figure 1: Immune complex vaccine strategy utilizes Fab- and Fc-mediated activities to stimulate robust Ab response against targeted epitopes on gp120

Neutralizing Epitopes on HIV Env

Conserved neutralizing Env epitopes have been identified based on their recognition by broadly reactive monoclonal Abs (mAbs) [5]. In the gp120 subunit, these epitopes are associated with the CD4-binding site, the chemokine-receptor binding site, which encompasses the V3 loop and the bridging sheet (CD4-induced, CD4i), and N-linked glycans decorating the surface of gp120. Recently, other conserved epitopes recognized by highly potent and cross reactive neutralizing mAbs VRC01-VRC03, PG9/16, CH01-CH04, PGT121-PGT145 [26-30] was discovered. The epitopes recognized by mAbs VRC01-VRC03 are mapped to the CD4-binding site, while the other epitopes involve N-linked glycans and conserved elements in the V1V2 and/or V3 loops. However, despite conservation of these epitopes among a large number of circulating HIV-1 isolates, Abs against these epitopes are produced only in a small fraction of HIV-1+ individuals [20,31,32]. For example, only 21% of the top 1-5% HIV+ subjects with broadly neutralizing serum activities (“elite neutralizers”) produce PG9/16-like Abs [31]. Immunization with vaccines bearing different gp120 epitopes also has failed to elicit broadly neutralizing Abs. These data indicate the poor immunogenicity of these epitopes as naturally presented on gp120. Hence, our lab has explored a strategy of utilizing immune complexes made of gp120 and selected anti-gp120 monoclonal Abs in order to improve immunogenicity of critical neutralizing epitopes such that Abs can be elicited against these epitopes by active immunization (Figure 1).

Immune Complex Vaccines

The capacity of immune complexes to augment antibody (Ab) responses in an antigen-specific manner is well documented [33]. Indeed, immune complexes have been tested as vaccines to augment Ab responses to hepatitis B surface antigen [34,35], infectious bursal disease virus [36], equine herpesvirus 1 [37], and porcine parvovirus [37,38]. A recent study also shows the utility of immune complexes, without any additional adjuvants, as intranasal vaccines against F. tularensis to induce protective mucosal immunity [39]. Similarly, we have demonstrated the ability of a gp120/mAb complex, but not uncomplexed gp120, administered in physiologic saline to elicit primary and secondary anti-gp120 antibody responses [40], indicating the function of Abs as a natural adjuvant. These adjuvant effects have been attributed, for the most part, to activities of the Fc fragment [41]. The interaction of immune complexes with Fc receptors on antigenpresenting cells facilitates antigen uptake, processing and presentation to augment CD4 T cell responses [42]. Additionally, immune complexes may be captured by and retained in follicular dendritic cells in the lymphoid follicles, which effectively increase the antigen concentration and half-life, leading to enhanced B cell activation and Ab production [33].

In addition to Fc, Fab activity also contributes to the immune complex capacity to modulate Ab responses. Upon binding to its antigen, Ab can alter the stability and conformation of the antigen, while exposing or shielding specific epitopes [43]. Previous studies with model antigens such as dinitrophenylated keyhole limpet hemocyanin (DNP-KLH), gamma globulin, and albumin showed that immunization with immune complexes results in quantitatively and qualitatively different Ab responses than with antigens alone [33]. Immunization with Streptococcus mutans adhesin P1 coupled with an anti-P1 mAb elicited Abs of different specificities from immunization with the P1 antigen alone or with the P1 antigen coated with other mAbs [44,45]. Similarly, differences in the quality of immune responses were reported after immunization with hepatitis B surface antigen (HBsAg) protein subunits S and PreS2 bound by different mAbs [46] and HIV-1 gp120 antigen in complex with soluble CD4 or anti-V3 mAb as compared to unbound gp120 [47]. Conversely, the Fab fragment on immune complexes has been implicated in epitope masking that prevents B cell recognition, resulting in suppression of immune responses. One well-studied example is anti-Rhesus D IgG given to Rhesus-negative women during pregnancy or after delivery of a Rhesus-positive baby to block active immune response against Rhesus D and prevent hemolytic disease by the maternal IgG [48]. Experimental results in the murine model show that the levels of suppression correlate with IgG affinity; furthermore, suppressive activity occurs without affecting T cell priming and does not require FcγRs [49,50], indicating that anti-Rhesus D IgG activity is most likely due to masking of Ab epitopes. Nevertheless, in humans, the engagement of the inhibitory FcγRIIB receptor may also contribute to the suppression of the anti-Rhesus D response. Thus, immune complexes via their Fab fragments can enhance or suppress Ab responses in a highly epitope- specific fashion. In our lab, we take advantage of this special property as a vaccine strategy to focus and augment the Ab responses toward the desired neutralizing Ab epitopes on HIV gp120.

gp120 Structural Alterations by Abs

HIV gp120 has an exceptionally dynamic structure. Its flexible elements include not only the highly mobile and variable loops, but also the inner and outer domains of gp120 core that are capable of adopting fluctuating conformations which shift toward and away from the formation of the Phe43 pocket in the CD4-binding site and that of the bridging sheet in the chemokine receptor binding site [17,51,52]. Upon CD4 binding, gp120 undergoes extensive structural changes that lock both inner and outer domains of gp120 into a more rigid structure, creating and stabilizing the CD4-binding pocket and the chemokine receptor binding site [17,53]. This is consistent with the thermodynamic analyses showing the unusually large negative changes of enthalpy and entropy in gp120 triggered by CD4 binding, with refolding and reordering of as many as 65 amino acid residues during the interaction of gp120 with CD4 [17,51].

MAb binding to gp120 also triggers substantial changes and stabilizes the gp120 structure, albeit at conformations distinct from that induced by CD4. For example, comparing the CD4-bound gp120 vs. mAb b12-bound gp120 structures shows that although CD4 and mAb b12 bind to overlapping surfaces on gp120, unlike CD4, mAb b12 induces and stabilizes a gp120 conformation that does not allow gp120 interaction with the chemokine receptor. By contrast, mAb A32 exposes and stabilizes the bridging sheet of the chemokine receptor binding site that contains the so-called CD4-induced epitopes [54]. Consistent with these findings, our studies show that the binding of different mAbs with gp120 induces antigenic alterations at sites outside those directly bound by the mAbs [40,55,56] (Figure 1). Hence, mAb binding to the CD4bs enhances antigenicity of epitopes in the V3 loop. MAbs to the V2 loop also enhance antigenicity of V3, whereas mAbs to C2 have little effect on V3 [40]. These results are in agreement with an earlier study conducted with a different panel of mAbs [57], demonstrating the ability of selected anti-gp120 mAbs to modulate the exposure and stability of particular gp120 epitopes for better Ab recognition. These modulatory effects are determined by the fine specificity of the mAbs, indicative of Fab-mediated activity. Nevertheless, the capacity of Fab fragments, as compared to intact IgG, to enhance antigenicity of the specific epitopes has not been directly tested.

gp120-Mab Complex Vaccines to Elicit HIV-Neutralizing Abs

As immune complexes made with gp120 and anti-CD4-binding site mAbs display enhanced V3 reactivity with cross-reactive neutralizing anti-V3 mAbs such as 447-52D, we tested these complexes as vaccines in mice for their capacity to elicit Abs against neutralizing V3 epitopes. In multiple experiments, the immune complexes consistently elicited higher titers of serum Abs to gp120 and V3 as compared to gp120 alone or gp120 mixed with a control irrelevant mAb [40,56]. Induction of Ab response was also faster in immune complex-immunized animals. High titers of anti-gp120 and anti-V3 Abs were generated after two injections of the immune complex, while uncomplexed gp120 elicited detectable anti- gp120 Ab response but only after three injections; similarly, it failed to stimulate any anti-V3 Abs even after four injections [56]. Importantly, the Ab response induced by the complexes had potent virus-neutralizing activities (Figure 2) which, as shown in peptide blocking experiments, were mediated to a significant extent by anti-V3 Abs [40,56]. Abs to the CD4-binding site was not induced, as the site was blocked by the mAbs used to form the complexes [56]. In contrast, uncomplexed gp120 administered on its own with the same immunization method or with a DNA priming/protein boost regimen did not stimulate any detectable neutralizing Abs (IC50 titers of <50) (Figure 2 and [40,55]). We also noted that both IgG1 and IgA specific for gp120 were generated by the complexes, while the uncomplexed gp120 failed to elicit any IgA response [56]. Epitope mapping further showed that the enhanced Ab response was specifically directed to V3 [56]. Immune complexes made with two different anti-CD4bs mAbs (654-D or 559/64-D) elicited comparably high titers of anti-V3 Abs, whereas complexes made with anti-V3 or anti-C2 mAbs did not ([56] and unpublished data). When the anti-CD4bs mAb 654-D was used to construct immune complexes with gp120s from two different HIV-1 strains (e.g. LAI and JRFL), the complexes induced similarly high titers of anti-V3 Abs, albeit with distinct and complementary cross-reactivity patterns [40]. These data indicate that the observed enhancement of V3 immunogenicity is not simply due to the conventional Fc-mediated activity on any gp120/mAb immune complexes; rather, they are associated with immune complexes formed with the anti-CD4-binding site mAbs.

aids-clinical-research-neutralizing-elicited-complexes

Figure 2: Neutralizing antibody response elicited by uncomplexed gp120 versus gp120/mAb complexes

It is important to point out, however, that Fc-mediated activities of our gp120/Ab complex vaccines might not have been exploited to their full potential, since human mAbs (IgG1) were used to form the complexes, and immunization experiments were done in mice. The association constant of human IgG1 Fc for mouse splenic macrophages is lower than that to human peripheral monocytes. Different binding modes were also reported for human IgG1 Fc binding to mouse vs. human Fc receptors expressed on mononuclear cells [58,59]. Hence, future studies should include experiments in transgenic mice expressing human FcRs or non-human primates to fully access the capacity of gp120/mAb complex vaccines to augment Ab responses to V3 and other critical epitopes on gp120.

Improving Potency and Breadth of Neutralizing Antibodies Elicited by gp120/mAb Complexes

N-linked glycans shielding most of surface gp120 modulate the exposure of critical neutralizing epitopes on this antigen, and removal of specific N-linked glycans increases virus susceptibility to neutralizing antibodies against different epitopes [7,8,12-16]. Immunization with Env mutant lacking a glycan in the stem of V2 loop results in higher and broader serum neutralizing Ab responses than that with wild type Env, indicating that more effective Env immunogens may be generated by removal of select N-glycan(s) [13]. Our studies identified a glycan associated with Asn at position 448 (N448) in the C4 region of gp120 that plays a role in modulating the processing and presentation of nearby T helper epitopes [60,61]. Interestingly, removal of this glycan also improves V3 reactivity with a broadly neutralizing mAb, without affecting other Ab epitopes or CD4-binding. When immune complexes containing gp120 mutants (N448Q or N448E) and the anti-CD4- binding site mAb 654-D were used for immunizing mice, significantly higher titers of neutralizing Ab responses were elicited as compared to those raised by the wild type gp120/654-D complex (Figure 1) [55]. Peptide blocking experiments showed that neutralization was mediated in part by anti-V3 Abs, but Abs against undefined epitopes also played a role [55]. The mutated gp120 proteins alone administered by DNA priming/protein boost were unable to elicit neutralizing Abs (IC50 titers of <50 [55], indicating that enhanced V3 antigenicity (i.e. in vitro Ab reactivity) of the gp120 mutants is not sufficient for improving V3 immunogenicity in vivo and other important factors exist that govern epitope immunogenicity (discussed in the next section).

Our initial studies were performed with immune complexes made of gp120LAI. The V3 sequence of gp120LAI is unusual, even among subtype B viruses, as it has a two amino acid insertion at the arch or tip of the V3 crown and multiple non-conserved substitutions and a single deletion at both flanking sides (Figure 2). Predictably, the binding and neutralizing activities of anti-V3 Abs generated by wild type gp120LAI/654-D and mutant gp120LAI/654-D complexes were highly restricted for the homologous virus (Figure 2) [55]. A more representative subtype B gp120 was tested as an immunogen for potential capacity to generate binding and neutralizing Abs that are more reactive to a larger array of subtype B viruses. V3 of gp120JRFL is identical to that of the subtype B consensus and gp120JRFL sequence has 91% similarity with consensus B gp120. Immunization with gp120JRFL/654-D generated more crossreactive anti-V3 Abs recognizing both homologous and heterologous V3 peptides (Figure 3A). The Abs also had neutralizing activities against heterologous Tier 1 viruses known to be highly sensitive to anti-V3 Abs (SF162, MN, SS1196.1 and 3988.25) (Figure 3B and [40]). Interestingly, the Abs failed to bind to V3LAI peptide and did not neutralize LAI virus, demonstrating complementary binding and neutralizing patterns of Abs generated by gp120LAI/654-D and gp120JRFL/654-D complexes. Nevertheless, although anti-V3 Ab response elicited by the gp120JRFL/654-D complex was reactive with the homologous V3JRFL peptide, the Abs was not able to neutralize JRFL virus. The Abs also were ineffective against other Tier 2 viruses such as YU-2 (Figure 3B), which are known to be relatively resistant to neutralization by anti-V3 Abs [62]. These data indicate that induction of Abs against other epitopes would be needed to target these V3-resistant viruses. As mAb binding to gp120 also modulates antigenicity of cross-reactive neutralizing epitopes in the CD4-binding site and the chemokine receptor binding sites outside V3 [57], additional new novel gp120/mAb complexes may be constructed to induce and skew Ab responses toward these epitopes. Currently, our lab aims to identify gp120/mAb complexes with enhanced antigenicity of epitopes in the CD4-binding sites and in the V1V2/V3 loops, and investigate their immunogenic properties following immunization. Moreover, there is renewed interest in the ability of Abs to mediate other non-neutralizing anti-viral functions and future studies will explore the capacity of Abs elicited by immune complex vaccines to contribute to ADCC, ADCVI, C'-mediated virus lysis, and other activities beyond virus neutralization.

aids-clinical-research-complementary-neutralizing-immune

Figure 3: Complementary patterns of binding and neutralizing anti-V3 Abs generated by immune complexes made with gp120LAI versus gp120JRFL

Immunological Parameters that Contribute to Enhanced Immunogenicity of gp120/mAb Complexes

To further improve the immunogenicity of epitopes that HIV vaccines and to design more effective immunogens presenting these epitopes, a better understanding of factors governing epitope immunogenicity is needed. From our recent efforts to augment V3 immunogenicity by a combination of immune complex vaccine strategy and N-glycan removal, immunological parameters that do and do not correlate with enhanced immunogenicity are revealed (Table 1).

Immunogen Neutralizing Ab activitya Antigenicityb Proteolytic degradationc Helper T cell responsed
wt - + + ++
N448Q - ++ ++ +++
wt/654-D + ++ ++ +
N448Q/654-D ++ +++ + +

Table 1: Immunological parameters of V3 epitopes presented on wild type or mutant gp120 on its own or as immune complexes with mAb 654-D.

In vitro antigenicity

As described, mAb binding to gp120 alters gp120 conformation that affects exposure and reactivity of epitopes on this antigen. Indeed, immune complexes of gp120 and anti-CD4-binding site mAb 654-D that elicited anti-V3 Abs displayed enhanced V3 antigenicity as demonstrated by significantly higher reactivity of anti-V3 mAbs to the complexes than to uncomplexed gp120 (Table 1) [40,55]. Further increase in V3 antigenicity was observed with N448Q gp120 mutant complexed with the same mAb, resulting in induction of more elevated titers of neutralizing Abs than achieved by the wild type complex. These data indicate a direct correlation between V3 immunogenicity in vivo and in vitro antigenicity. However, antigenicity is not the only parameter influencing immunogenicity. Antigenicity of an epitope in the N-terminal C1 region, like V3, was also enhanced when presented on gp120/mAb 654-D complexes, but in vivo Ab response to C1 was unaltered [40,56]. Similarly, as mentioned and shown in Table 1, V3 epitopes were better recognized on N448Q gp120 than on wild type gp120, but this enhancement was not sufficient for the mutant gp120 on its own to induce anti-V3 Ab response. These data suggest that epitope immunogenicity is not governed only by its antigenicity and that assessment of candidate vaccine immunogens should go beyond measurement of antigenicity alone.

Sensitivity to proteolytic degradation

Increased exposure of V3 that leads to its better recognition by Abs may also render V3 epitopes more accessible and sensitive to degradative enzymes. Yu et al. [63] identified that many proteolytic cleavage sites on gp120 recognized by endolysosomal proteases important for antigen processing and presentation cluster in conserved regions associated with receptor binding sites and cross-reactive neutralizing epitopes including V3. Proteolytic degradation of the epitopes would prevent generation of Ab response against conformation-dependent epitopes recognized by most virus-neutralizing Abs. Our studies show that although V3 antigenicity was augmented by N448-glycan removal, the mutation also rendered V3 epitopes more susceptible to cathepsin L and the mutant protein was not able to induce anti-V3 Abs on its own (Table 1). However, when complexed with the anti-CD4-binding site mAb 654-D, it potently stimulated neutralizing anti-V3 Ab response to titers higher than those attained by the wild type gp120/654-D complex. Interestingly, V3 epitopes on the mutant gp120/654-D complex were not only most antigenic (i.e. best recognized by anti-V3 mAbs) but also most resistant to proteolysis. This is consistent with earlier findings in our lab and others [52,64] that demonstrate the capacity of anti-CD4- binding site mAbs, similar to CD4, to stabilize gp120 and increase its resistance against degradation by proteases and endoglycosidases as a result of substantial thermodynamic changes induced by mAb binding to gp120 [51]. Collectively, these data indicate that improvement of V3 immunogenicity can be achieved by augmenting both antigenicity and proteolytic resistance. Whether the same principles govern immunogenicity of other epitopes on the viral Env remain to be determined, but they provide rational testable strategies in designing novel immunogens to present specific Ab epitopes that vaccines aim to target.

Helper T cell response

As described, Abs facilitate antigen uptake and modulate antigen processing and presentation for MHC class II-restricted helper CD4 T cells. It is of interest to point out that while gp120/mAb 654- D complexes are potent immunogens for elicitation of neutralizing Ab responses, 654-D and other mAbs to the CD4-binding site have suppressive effects on MHC class II presentation of gp120 [64-66]. As Abs directed to other regions of gp120 cause no inhibition, it is apparent that this effect is specific for anti-CD4-binding site Abs. gp120 bound by the anti-CD4-binding site mAbs is ingested and transported into the acidic endolysosomes of antigen presenting cells [64,65]. However, the complexes of gp120 and anti-CD4bs mAbs remain stable at the acidic pH of the endolysosomes [64] and are resistant to proteolytic digestion by endosomal enzymes [64,65], such that gp120 antigen processing is obstructed and helper epitope peptides are not efficiently generated and presented on MHC class II to CD4 T cells. The mAbs do not have negative effects on the T cell themselves, as the T cell response to synthetic peptides representing already processed gp120 epitopes is not affected by the anti-CD4bs mAbs [67]. T cells specific for other antigens, such as HIV-1 gag p24, Mycobacterium tuberculosis antigens, cytomegalovirus, are also not affected by the mAbs or the immune complexes [67]. Notably, the obstructive effect of the anti-CD4bs mAbs on gp120 antigen processing is not simply due to steric hindrance of a particular helper epitope by the mAbs. These mAbs inhibit the processing and presentation of helper epitopes in the C1, C2, V2, or V3 regions distant from the CD4 binding site [56,65,67], indicative of their global effects. In support of these in vitro data, immunization of mice with the gp120/mAb 654-D complex resulted in a lower level of gp120-specific lymphoproliferation than that with uncomplexed gp120 or a different complex made with an anti-C5 mAb [66]. Reduced proliferation was also seen in response to multiple overlapping peptides spanning the entire gp120, indicating that the mAb suppresses CD4 T cell responses to various epitopes on gp120. Hence, Ab binding to the CD4-binding site of gp120 modulates CD4 T cell and Ab responses to gp120 in disparate ways. In contrast, the N448Q mutation has enhancing effects on CD4 T cell response, but the protein alone does not elicit neutralizing Abs and only immunization with the N448Q/654-D complex elicits high titers of neutralizing Abs. Enhanced Ab response induced by these immune complexes occurs in the absence of optimal helper CD4 T cell response to gp120, and this opens another venue to exploit for improving this vaccine strategy (Table 2). New adjuvants incorporating multiple TLR ligands such as TLR-9 ligand CpG-ODN and TLR7/8 ligand resiquimod (R848) may be utilized in order to elicit both B cell and T cell responses [68,69]. In addition, a vaccine regimen that combines DNA or other vectors expressing gp120 to elicit T cells and the gp120/654-D complex to stimulate Abs is currently being investigated for the capacity to generate a balanced immune response that confers more potent and durable anti-viral immunity.

Potency Breadth
Immune complexes constructed with gp120 mutants lacking specific N- glycans to better expose targeted epitopes Immune complexes formed with different gp120 antigens displaying distinct variants of targeted epitopes
Adjuvants targeting different TLRs or other pathogen recognition receptors Immune complexes formed with different mAbs to enhance immunogenicity of different epitopes targeted on gp120
Use of gp120/mAb complexes as boosting immunogens following priming with DNA or other vectors A cocktail of immune complexes to target multiple different epitopes and epitope variants

Table 2: Approaches to further improve the potency and breadth of Ab responses elicited by immune complex vaccines.

Conclusion

To prevent infection of a large array of circulating HIV-1 isolates, HIV vaccines need to induce high titers of Ab responses that simultaneously target multiple critical epitopes on the virus Env and multiple variants within each of the epitopes. Using V3 as a prototype, we demonstrated the utilization of immune complex vaccine strategy to augment V3 immunogenicity. We provide evidence that immune complex vaccines are capable of inducing high titers of neutralizing Ab responses directed to V3. Induction of neutralizing Abs specific for distinct V3 variants is also attained by immunization with immune complexes made of different gp120 proteins. Current efforts are aimed to tackle the challenge whether the immune complex vaccines may also be exploited for eliciting high titers of Ab responses against potent neutralizing epitopes in the CD4-binding site and/or recently identified epitopes involving N-linked glycans and other conserved elements in the V1, V2, and V3 loops (Table 2). We envision that a vaccine may be developed that will incorporate multiple immune complexes to target the different epitopes and their distinct variants, and that such complexes will ultimately be combined with DNA or other vectors to stimulate balanced antibody and T cell responses that confer durable immunity against HIV.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11773
  • [From(publication date):
    specialissue-2012 - Aug 22, 2017]
  • Breakdown by view type
  • HTML page views : 7996
  • PDF downloads :3777
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords